BMY RSI
As of date:1/27/2023
BMY stock price:72.45
BMY RSI:47.23
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)47.23
Extremely
Oversold

Also see:
BMY Market Cap History
BMY Shares Outstanding History
BMY YTD Return
BMY DMA
BMY MACD
BMY Technical Analysis

Bullish Two Hundred Day Moving Average Cross - DRVN
1 hour, 23 minutes ago


Bullish Two Hundred Day Moving Average Cross - ASTL
1 hour, 23 minutes ago


TFS Financial Breaks Below 200-Day Moving Average - Notable for TFSL
1 hour, 25 minutes ago


GDS Makes Notable Cross Below Critical Moving Average
1 hour, 26 minutes ago


MeiraGTx Holdings (MGTX) Shares Cross Above 200 DMA
1 hour, 26 minutes ago


GrowGeneration (GRWG) Shares Cross Above 200 DMA
1 hour, 26 minutes ago


Southside Bancshares Breaks Above 200-Day Moving Average - Bullish for SBSI
1 hour, 42 minutes ago


CTI BioPharma Breaks Below 200-Day Moving Average - Notable for CTIC
1 hour, 49 minutes ago


Cincinnati Financial Breaks Above 200-Day Moving Average - Bullish for CINF
1 hour, 50 minutes ago


Bullish Two Hundred Day Moving Average Cross - BBU
2 hours, 2 minutes ago


TVE Makes Notable Cross Below Critical Moving Average
2 hours, 7 minutes ago


Williams Sonoma Breaks Above 200-Day Moving Average - Bullish for WSM
2 hours, 10 minutes ago


CrediCorp (BAP) Shares Cross Below 200 DMA
2 hours, 10 minutes ago


Lithia Motors (LAD) Shares Cross Above 200 DMA
2 hours, 10 minutes ago


Bullish Two Hundred Day Moving Average Cross - NHI
2 hours, 18 minutes ago


More Technical Analysis News

BMY RSIBMY DMA
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

When researching a stock like Bristol-Myers Squibb, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BMY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BMY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of these ways is called the Relative Strength Index, or RSI. This popular indicator, originally developed in the 1970's by J. Welles Wilder, looks at a 14-day moving average of a stock's gains on its up days, versus its losses on its down days. The resulting BMY RSI is a value that measures momentum, oscillating between "oversold" and "overbought" on a scale of zero to 100. A reading below 30 is viewed to be oversold, which a bullish investor could look to as a sign that the selling is in the process of exhausting itself, and look for entry point opportunities. A reading above 70 is viewed to be overbought, which could indicate that a rally in progress is starting to get crowded with buyers. If the rally has been a long one, that could be a sign that a pullback is overdue.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes

Email EnvelopeFree BMY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Video: RSI Indicator


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research RSI, below are some other companies in the same sector:

BSX RSI
CAH RSI
CI RSI
CNC RSI
COO RSI
CRL RSI
CTLT RSI
CVS RSI
DGX RSI
DHR RSI
More Healthcare companies »

 

BMY RSI | www.StockRSI.com | Copyright © 2019 - 2023, All Rights Reserved

Nothing in StockRSI.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.